BioAtla (BCAB) Assets Average (2021 - 2026)
BioAtla's (BCAB) quarterly Assets Average came in at $9.0 million in Q2 2026, down 72.37% on a YoY basis from $32.7 million in Q2 2025, and down 19.3% quarter-over-quarter from $11.2 million in Q1 2026.
Analysis
BioAtla (BCAB) Assets Average (2021 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Assets Average for 6 consecutive years, with $9.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average fell 72.37% year-over-year to $9.0 million; the trailing twelve-month figure through Jun 2026 stood at $9.0 million (down 72.37% YoY), and the FY2025 full-year result was $33.1 million, down 61.5% from the prior year.
- Assets Average slipped to $9.0 million in Q2 2026 per BCAB's latest filing, from $11.2 million in the prior quarter.
- Across five years, Assets Average topped out at $242.5 million in Q1 2022 and bottomed at $9.0 million in Q2 2026.
- Historically, Assets Average has averaged $112.4 million across 5 years, with a median of $91.7 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Assets Average grew 2.33% in 2022, then sank 75.31% in 2026.
- Over 5 years, Assets Average stood at $207.4 million in 2022, then tumbled by 34.67% to $135.5 million in 2023, then tumbled by 57.69% to $57.3 million in 2024, then slumped by 74.07% to $14.9 million in 2025, then plunged by 39.23% to $9.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $9.0 million, $11.2 million, and $14.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.17 Bn | 193.18 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.74 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.28 Bn | 48.14 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | 5.51 Bn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 9.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.04 Mn |
| Mar 31, 2026 | 11.20 Mn |
| Dec 31, 2025 | 14.87 Mn |
| Sep 30, 2025 | 21.52 Mn |
| Jun 30, 2025 | 32.71 Mn |
| Mar 31, 2025 | 45.36 Mn |
| Dec 31, 2024 | 57.33 Mn |
| Sep 30, 2024 | 65.44 Mn |
| Jun 30, 2024 | 78.92 Mn |
| Mar 31, 2024 | 104.43 Mn |
| Dec 31, 2023 | 135.51 Mn |
| Sep 30, 2023 | 165.50 Mn |
| Jun 30, 2023 | 192.09 Mn |
| Mar 31, 2023 | 215.14 Mn |
| Dec 31, 2022 | 207.42 Mn |
| Sep 30, 2022 | 201.30 Mn |
| Jun 30, 2022 | 222.07 Mn |
| Mar 31, 2022 | 242.54 Mn |
| Dec 31, 2021 | 266.00 Mn |
| Sep 30, 2021 | 247.14 Mn |